Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $11.76 in the prior trading day, NovoCure Ltd (NASDAQ: NVCR) closed at $12.11, up 2.98%. In other words, the price has increased by $2.98 from its previous closing price. On the day, 2.25 million shares were traded. NVCR stock price reached its highest trading level at $12.21 during the session, while it also had its lowest trading level at $11.74.
Ratios:
Our goal is to gain a better understanding of NVCR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 0.70.
On July 08, 2025, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $30.
Evercore ISI Upgraded its In-line to Outperform on December 02, 2024, whereas the target price for the stock was revised from $18 to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 05 ’25 when Cordova Ashley bought 81,550 shares for $12.22 per share. The transaction valued at 996,859 led to the insider holds 437,569 shares of the business.
Brackmann Christoph bought 20,000 shares of NVCR for $231,800 on Jul 29 ’25. The Chief Financial Officer now owns 141,150 shares after completing the transaction at $11.59 per share. On Jun 03 ’25, another insider, Stafford Kristin, who serves as the Director of the company, sold 999 shares for $17.28 each. As a result, the insider received 17,259 and left with 3,054 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 1356101760 and an Enterprise Value of 1120541824. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.11 while its Price-to-Book (P/B) ratio in mrq is 3.97. Its current Enterprise Value per Revenue stands at 1.745 whereas that against EBITDA is -7.035.
Stock Price History:
The Beta on a monthly basis for NVCR is 0.74, which has changed by -0.57731235 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, NVCR has reached a high of $34.13, while it has fallen to a 52-week low of $10.70. The 50-Day Moving Average of the stock is -5.19%, while the 200-Day Moving Average is calculated to be -21.01%.
Shares Statistics:
The stock has traded on average 1.69M shares per day over the past 3-months and 1956970 shares per day over the last 10 days, according to various share statistics. A total of 111.98M shares are outstanding, with a floating share count of 100.42M. Insiders hold about 10.33% of the company’s shares, while institutions hold 82.92% stake in the company. Shares short for NVCR as of 1763078400 were 5971436 with a Short Ratio of 3.52, compared to 1760486400 on 5242339. Therefore, it implies a Short% of Shares Outstanding of 5971436 and a Short% of Float of 8.42.
Earnings Estimates
The performance of NovoCure Ltd (NVCR) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.32 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.31 and -$1.5 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.48, with 7.0 analysts recommending between -$1.19 and -$1.91.
Revenue Estimates
7 analysts predict $168.93M in revenue for. The current quarter. It ranges from a high estimate of $178.4M to a low estimate of $158.28M. As of. The current estimate, NovoCure Ltd’s year-ago sales were $161.27MFor the next quarter, 7 analysts are estimating revenue of $168.39M. There is a high estimate of $175.2M for the next quarter, whereas the lowest estimate is $159.37M.
A total of 7 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $663M, while the lowest revenue estimate was $639.29M, resulting in an average revenue estimate of $651.21M. In the same quarter a year ago, actual revenue was $605.22MBased on 7 analysts’ estimates, the company’s revenue will be $687.78M in the next fiscal year. The high estimate is $738.6M and the low estimate is $658.79M.
